Report Information More information from: https ://www.wis eguyreports .com/reports /495880
Boehringer Ingelheim GmbH - Product Pipeline Review 2016 Report / Search Code: WGR495880
Price
1-user P DF : $ 1500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 3000.0
Enterprise P DF : $ 4500.0
Boehringer Ingelheim GmbH - Product Pipeline Review - 2016 Summary Global Markets Direct’s , ‘Boehringer Ingelheim GmbH - Product Pipeline Review 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical res earch and development focus . The report provides comprehens ive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and the dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the pipeline therapeutic lands cape of Boehringer Ingelheim GmbH - The report provides overview of Boehringer Ingelheim GmbH including its bus ines s des cription, key facts , and locations and s ubs idiaries - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report as s es s es Boehringer Ingelheim GmbH’s pipeline therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report features Boehringer Ingelheim GmbH’s out-licens ed and partnered product portfolio and s ummarizes its dormant and dis continued projects Reas ons to buy - Evaluate Boehringer Ingelheim GmbH’s s trategic pos ition with total acces s to detailed information on its product pipeline - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Boehringer Ingelheim GmbH - Identify potential new clients or partners in the target demographic - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Boehringer Ingelheim GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Boehringer Ingelheim GmbH Snaps hot 6 Boehringer Ingelheim GmbH Overview 6 Key Information 6 Key Facts 6 Boehringer Ingelheim GmbH - Res earch and Development Overview 7 Key Therapeutic Areas 7 Boehringer Ingelheim GmbH - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licens ed Products 19 Boehringer Ingelheim GmbH - Pipeline Products Glance 21 Boehringer Ingelheim GmbH - Late Stage Pipeline Products 21 Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products 23 Boehringer Ingelheim GmbH - Early Stage Pipeline Products 26 Boehringer Ingelheim GmbH - Drug Profiles 29 (empagliflozin + linagliptin) 29 (linagliptin + metformin hydrochloride ER) 30 (olodaterol hydrochloride + tiotropium bromide) 31 idarucizumab 34 (empagliflozin + metformin hydrochloride XR) 35 adalimumab bios imilar 36 afatinib dimaleate 37 bevacizumab bios imilar 42 empagliflozin 43 nintedanib 45 ris ankizumab 50 rituximab bios imilar 52 volas ertib trihydrochloride 53 BI-1026706 56 BI-1361849 57 BI-144807 58 BI-409306 59 FX-125L 61 HM-61713 63 BI-836826 64 BI-836845 65 BI-836858 67 BI-1005273 68 BI-1060469 69 BI-113608 70 BI-416970 71 BI-425809 72 BI-443651 73 BI-655064 74 BI-655088 75 BI-655130 76 BI-685509 77 BI-836880 78 BI-836909 79 BI-853520 80 BI-860585 81 BI-894999 82 PXS-4728A 83 Small Molecule for Oncology 84 AR-116082 85 BI-113823 86 BI-1467335 87 BI-186908 88 BI-207524 Follow-Up 89 BI-703704 90 BI-882370 91 CNX-012 92 CNX-012570 93 linagliptin 94 Monoclonal Antibody for Ophthalmology 95 olcegepant 96 Small Molecule 2 for Oncology 98
Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 99 Small Molecule 3 for Oncology 100 Small Molecule for Res piratory Dis eas es 101 Small Molecule to Agonize Glucocorticoid Receptor for Inflammation 102 Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 103 Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection 104 Small Molecules for Res piratory Dis orders 105 Small Molecules to Inhibit HIV-1 Revers e Trans criptas e for HIV-1 Infection 106 Small Molecules to Inhibit TRPC4/C5 for Depres s ion, Anxiety and Nephropathy 107 Synthetic Peptide for CardioMetabolic Dis eas e 108 Antibody for Oncology 109 BI-665915 110 Small Molecule for HIV 111 Small Molecule for HIV-1 Infection 112 Small Molecule to Agonize Glucocorticoid Receptor 113 Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Dis orders 114 Small Molecules for Oncology 115 Small Molecules for Schizophrenia 116 Small Molecules for Undis clos ed Indication 117 Small Molecules to Inhibit K-Ras for Oncology 118 Small Molecules to Inhibit Kinas es for Oncology 119 Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Dis orders 120 Boehringer Ingelheim GmbH - Pipeline Analys is 121 Boehringer Ingelheim GmbH - Pipeline Products by Target 121 Boehringer Ingelheim GmbH - Pipeline Products by Route of Adminis tration 125 Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type 126 Boehringer Ingelheim GmbH - Pipeline Products by Mechanis m of Action 127 Boehringer Ingelheim GmbH - Recent Pipeline Updates 130 Boehringer Ingelheim GmbH - Dormant Projects 166 Boehringer Ingelheim GmbH - Dis continued Pipeline Products 169 Dis continued Pipeline Product Profiles 169 Boehringer Ingelheim GmbH - Company Statement 172 Boehringer Ingelheim GmbH - Locations And Subs idiaries 174 Head Office 174 Other Locations & Subs idiaries 174 Appendix 179 Methodology 179 Coverage 179 Secondary Res earch 179 Primary Res earch 179 Expert Panel Validation 179 Contact Us 179 Dis claimer 180 Lis t of Tables Boehringer Ingelheim GmbH, Key Information 12 Boehringer Ingelheim GmbH, Key Facts 12 Boehringer Ingelheim GmbH - Pipeline by Indication, 2016 14 Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016 20 Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016 21 Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016 22 Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016 23 Boehringer Ingelheim GmbH - Partnered Products / Combination Treatment Modalities , 2016 24 Boehringer Ingelheim GmbH - Out-Licens ed Products in Pipeline, 2016 25 Boehringer Ingelheim GmbH - Out-Licens ed Products / Combination Treatment Modalities , 2016 26 Boehringer Ingelheim GmbH - Pre-Regis tration, 2016 27 Boehringer Ingelheim GmbH - Phas e III, 2016 28 Boehringer Ingelheim GmbH - Phas e II, 2016 29 Boehringer Ingelheim GmbH - Phas e I, 2016 30 Boehringer Ingelheim GmbH - Preclinical, 2016 32 Boehringer Ingelheim GmbH - Dis covery, 2016 34 Boehringer Ingelheim GmbH - Pipeline by Target, 2016 127 Boehringer Ingelheim GmbH - Pipeline by Route of Adminis tration, 2016 131 Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016 132 Boehringer Ingelheim GmbH - Pipeline Products by Mechanis m of Action, 2016 133 Boehringer Ingelheim GmbH - Recent Pipeline Updates , 2016 136 Boehringer Ingelheim GmbH - Dormant Developmental Projects ,2016 172 Boehringer Ingelheim GmbH - Dis continued Pipeline Products , 2016 175 Boehringer Ingelheim GmbH, Subs idiaries 180 Lis t of Figures Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2016 14 Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016 20 Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016 21 Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016 22 Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016 23 Boehringer Ingelheim GmbH - Out-Licens ed Products in Pipeline, 2016 25 Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2016 127
Boehringer Ingelheim GmbH - Pipeline by Route of Adminis tration, 2016 131 Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016 132 Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanis m of Action, 2016 133
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349